Sustanon 250mg/ml

Product Description

Approx. 21 days Anabolic/Androgenic Steroid (for injection) 250-1000 mg/week (males only)


Active Life: Drug Class: Average Dose Men: Acne: Water Retention: High Blood Pressure: Liver Toxic: Aromatization: DHT Conversion: Decrease HPTA function:

Yes Yes Low Yes Yes, high Yes, severe

DESCRIPTION Testosterone propionate, testosterone phenylpropionate, testosterone isocaproate and testosterone decanoate are all white to creamy white crystals or powder. They are practically insoluble in water but are soluble in chloroform, ethanol and fixed oils. They have melting points in excess of 50°C. They are prepared synthetically from plant origins. They are fatty acid esters of the naturally occurring androgen testosterone.

Sustanon 250′ is a clear, colourless glass ampoule or vial containing 1 mL of pale yellow oily solution.

Composition Active

Each ampoule or vial of Sustanon ‘250’ contains 30 mg testosterone propionate, 60 mg testosterone phenylpropioncrte, 60 mg testosterone isocaproate and 100 mg testosterone decanoate in 1 mL arachis oil. All 4 compounds are esters of the natural hormone testosterone. The total amount of testosterone per mL is 176 mg.

Inactive excipients Arachis (peanut) oil; benzyl alcohol (10%).

Pharmacotherapeutic group: androgens. ATC code G03B A03


Pharmacodynamic properties

Treatment of hypogonadal men with Sustanon results in a clinically significant rise of plasma concentrations of testosterone, dihydrotestosterone, oestradiol and androstenedione, as well as a decrease of SHBG (sex hormone binding globulin). Luteinising hormone (LH) and follicle-stimulating hormone (FSH) are restored to the normal range. In hypogonadal men, treatment with Sustanon results in an improvement of testosterone deficiency symptoms. Moreover, treatment increases bone mineral density and lean body mass, and decreases body fat mass. Treatment also improves sexual function, including libido and erectile function. Treatment decreases serum LDL-C, HDL-C and triglycerides, increases haemoglobin and hemcrtocrit, whereas no clinically relevant changes to PSA have been reported. Treatment may result in an increase in prostate size, but no adverse effects on prostate symptoms have been observed. In hypogonadal diabetic patients, improvements of insulin sensitivity and/or reduction in blood glucose have been reported with the use of androgens. In female to male transsexuals treatment with androgens/Sustanon induces masculinisation.

Pharmacokinetic properties Sustanon 250′ contains 4 esters of testosterone with different duration of action. The esters are hydrolysed into the natural hormone testosterone as soon as they enter the general circulation. A single dose of Sustanon 250′ leads to an increase of total plasma testosterone with peak-levels of approximately 70 nmol/L (Cmax), which are reached approximately 24-48 h (max) after administration. Plasma testosterone levels return to the lower limit of the normal range in males in approximately 21 days. Distribution Testosterone displays high binding (over 97%) to plasma proteins and sex hormone binding globulin. Biotransformation Testosterone is metabolized to dihydrotestosterone and oestradiol, which are further metabolised via the normal pathways. Elimination Excretion mainly takes place via the urine as conjugates of etiocholanolone and androsterone.


  • In general, dosage should be adjusted according to the response of the individual patient. • Adults including elderly: Usually, one injection of ImL per three weeks is adequate for Sustanon 250′.

Sustanon should be administered by deep intramuscular injection. • Safety and efficacy have not been adequately determined in children and adolescents. Pre-pubertal children treated with Sustanon should be treated with caution. Sustanon contains benzyl alcohol and should not be given to children under 3 years of age.

OVERDOSAGE The acute toxicity of testosterone is low. There are no specific recommendations for the management of overdosage with Sustanon. If symptoms of chronic overdose occur (e.g. polycythemia, priapism) treatment should be discontinued and after disappearance of the symptoms, be resumed at a lower dosage.


Sustanon 250 Each mL of the oily solution contains: testosterone propionate 30mg testosterone isocaproate 60mg testosterone decanoate 100mg testosterone phenylpropionate 60mg Store below 30°C. Do not refrigerate and protect from light. Store in the original packaging and keep container in the outer carton. Since an opened ampoule cannot be resealed in such a way to further guarantee the sterility of the contents, the solution should be used immediately